Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.03 USD
Change Today +0.042 / 4.25%
Volume 264.5K
STEM On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 10:45 AM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

stemcells inc (STEM) Snapshot

Open
$0.99
Previous Close
$0.99
Day High
$1.07
Day Low
$0.99
52 Week High
07/3/14 - $2.43
52 Week Low
12/17/14 - $0.84
Market Cap
70.7M
Average Volume 10 Days
738.9K
EPS TTM
$-0.53
Shares Outstanding
69.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for STEMCELLS INC (STEM)

stemcells inc (STEM) Related Businessweek News

No Related Businessweek News Found

stemcells inc (STEM) Details

StemCells, Inc., a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development. It engages in clinical development of its platform technology, HuCNS-SC, a purified human neural stem cells used as a potential treatment for disorders of the central nervous system. The company has completed Phase I/II clinical trial for the treatment of chronic spinal cord injury; and Phase I clinical trial for the treatment of Pelizaeus-Merzbacher disease, as well as completed enrollment and treatment in its Phase I/II clinical trial in geographic atrophy of age-related macular degeneration that cause blindness in the elderly. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.

69 Employees
Last Reported Date: 03/13/15
Founded in 1988

stemcells inc (STEM) Top Compensated Officers

Chief Executive Officer, Chief Executive Offi...
Total Annual Compensation: $835.8K
Executive Vice President of Scientific & Stra...
Total Annual Compensation: $457.3K
Compensation as of Fiscal Year 2013.

stemcells inc (STEM) Key Developments

StemCells, Inc. Appoints Ian Massey as President and Chief Operating Officer

StemCells Inc. announced that Ian Massey has joined its executive team as President and Chief Operating Officer, effective March, March 23, 2015. In this new role, Dr. Massey has direct responsibility for all aspects of the company's research and development, manufacturing, regulatory affairs, and quality assurance activities. He reports to Martin McGlynn, the company's Chief Executive Officer. Most recently, he was the COO and President of U.S. Operations of Biotie Therapies Corporation.

StemCells Inc. Reports Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014; Reports Impairment of Goodwill and Other Intangible Assets for the Fourth Quarter Ended December 31, 2014; Plans to Initiate Controlled Proof-Of-Concept Phase II Study in Geographic Atrophy of Dry Age Related Macular Degeneration

StemCells Inc. reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014. For the fourth quarter of 2014, the company reported a net loss of $10,108,000 from continuing operations and net loss of $10,249,000 or $0.15 per basic and diluted share, in comparison, for the fourth quarter of 2013, the company reported a net loss of $6,848,000 from continuing operations and net loss of $6,963,000, or $0.13 per basic and diluted share. Non-GAAP net loss was $9,330,000 or $0.14 per basic and diluted share, in comparison, for the fourth quarter of 2013, the company reported a non-GAAP net loss of $8,887,000 or $0.16 per basic and diluted share. Total revenue from continuing operations was $883,000, compared to $45,000 in the same period of 2013. Revenue from continuing operations is primarily from royalties and milestone payments received under various licensing agreements. Loss from operations was $9.729 million compared to $9.296 million a year ago. For the full year 2014, the company reported a net loss of $32,741,000, or $0.53 per share, compared with a net loss of $26,439,000, or $0.61 per basic and diluted share, for 2013. Non-GAAP net loss was $29,381,000 or $0.48 per basic and diluted share, comparison, for the fourth quarter of 2013; the company reported a non-GAAP net loss of $26,024,000 or $0.60 per basic and diluted share. The approximately $3,400,000 increase is primarily associated with increased levels of clinical activity. Total revenue from continuing operations was $1,012,000 compared to $172,000 for 2013. The increase in 2014 was primarily attributable to a milestone payment of approximately $500,000 received under a licensing agreement with ReNeuron Ltd. and a licensing fee of approximately $400,000 in connection with divestiture of the SC Proven business entered into with Takara Bio Inc. Cash used in operations totaled $27,352,000, compared to $23,322,000 in 2013. Loss from operations was $30.910 million compared to $28.093 million a year ago. The company reported wrote-off approximately $2,440,000 in goodwill and other intangible assets related to its discontinued SC Proven business and other technology not related to therapeutic product development programs for the fourth quarter ended December 31, 2014. The company announced that it will shortly initiate a controlled proof-of-concept Phase II study in geographic atrophy of dry age related macular degeneration, advanced form of the disease and a cause of blindness in the elderly.

StemCells Inc. Presents at 25th Annual Institutional Investor Conference, Mar-19-2015 10:35 AM

StemCells Inc. Presents at 25th Annual Institutional Investor Conference, Mar-19-2015 10:35 AM. Venue: The University Club, 1 W 54th St, New York, NY 10019, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STEM:US $1.03 USD +0.042

STEM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioheart Inc $0.0091 USD -0.0012
Biorestorative Therapies Inc $0.40 USD 0.00
IntelliCell BioSciences Inc $0.0001 USD 0.00
International Stem Cell Corp $0.06 USD -0.0016
Nuo Therapeutics Inc $0.26 USD +0.001
View Industry Companies
 

Industry Analysis

STEM

Industry Average

Valuation STEM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 11.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 28.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEMCELLS INC, please visit www.stemcellsinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.